美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Lakewood-Amedex Biotherapeutics (Direct Listing)

2.13

-0.1100-4.91%

盘后：2.200.0700+3.29%16:47 EDT

成交量：3.95万

成交额：8.60万

市值：504.75万

市盈率：-0.21

高：2.29

开：2.20

低：2.10

收：2.24

52周最高：98.20

52周最低：1.66

股本：236.97万

流通股本：141.56万

量比：0.53

换手率：2.79%

股息：- -

股息率：- -

每股收益(TTM):-10.2000

每股收益(LYR):-8.3987

净资产收益率：-402.84%

总资产收益率：-139.40%

市净率：1.17

市盈率(LYR):-0.25

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Lakewood-Amedex Biotherapeutics (Direct Listing)

交易所：

NASDAQ

成立时间：

2006

员工人数：

- -

公司地址：

8031 Cooper Creek Blvd.,Suite 103,University Park,Florida,United States

官网：

http://lakewoodamedex.com

邮编：

34201

电话：

传真：

- -

简介：

Lakewood-Amedex Biotherapeutics Inc.最初于2006年7月11日在特拉华州注册成立。该公司是一家私营制药公司，专注于通过开发其双磷酸霉素来应对抗菌素耐药性（AMR）的全球健康危机类抗菌剂。该公司的方法涉及一种新机制，旨在迅速破坏细菌膜的稳定性，这可能会降低耐药性发展的可能性。他们的先导化合物Nu-3目前正处于治疗感染的糖尿病足溃疡的临床试验中，被配制为外用凝胶，可提供快速的抗菌作用和靶向递送。除了糖尿病足溃疡，该公司正在探索在治疗复杂的尿路感染和肺部感染方面的应用。

董事

名称

职位

Doug Manion

Chairman of the Board and Independent Director

Kelvin Cooper

Chief Executive Officer,Director and SVP Research & Development

Joseph Tucker

Independent Director

Leonard J. DeRoma

Independent Director

股东

名称

职位

Kelvin Cooper

Chief Executive Officer,Director and SVP Research & Development

Peter Ceccacci

Chief Financial Officer and VP Administration

Thomas Balzer

Chief Medical Officer and SVP Clinical Development

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/LABT/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","market":"US","secType":"STK","nameCN":"Lakewood-Amedex Biotherapeutics (Direct Listing)","latestPrice":2.13,"timestamp":1787601600000,"preClose":2.24,"halted":0,"volume":39530,"hourTrading":{"tag":"盘后","latestPrice":2.2,"preClose":2.13,"latestTime":"16:47 EDT","volume":2366,"amount":5189.3156223999995,"timestamp":1787604434261,"change":0.07,"changeRate":0.032864,"amplitude":0.079812},"delay":0,"changeRate":-0.049107142857142995,"floatShares":1415552,"shares":2369700,"eps":-10.199959,"marketStatus":"盘后交易","change":-0.11,"latestTime":"08-24 16:56:20 EDT","open":2.2,"high":2.29,"low":2.1,"amount":85964.875079,"amplitude":0.084821,"askPrice":2.25,"askSize":50,"bidPrice":2.12,"bidSize":49,"shortable":3,"etf":0,"ttmEps":-10.199959,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"listingDate":1776916800000,"exchange":"NASDAQ","adjPreClose":2.24,"preHourTrading":{"tag":"盘前","latestPrice":2.2,"preClose":2.24,"latestTime":"09:28 EDT","volume":1059,"amount":2400.443772,"timestamp":1787578082120,"change":-0.04,"changeRate":-0.017857,"amplitude":0.093616},"postHourTrading":{"tag":"盘后","latestPrice":2.2,"preClose":2.13,"latestTime":"16:47 EDT","volume":2366,"amount":5189.3156223999995,"timestamp":1787604434261,"change":0.07,"changeRate":0.032864,"amplitude":0.079812},"volumeRatio":0.532405},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","floatShares":1415552,"roa":"-139.40%","roe":"-402.84%","lyrEps":-8.39872,"volumeRatio":0.532405,"shares":2369700,"dividePrice":0,"high":2.29,"amplitude":0.084821,"preClose":2.24,"low":2.1,"week52Low":1.66,"pbRate":"1.17","week52High":98.2,"institutionHeld":0,"latestPrice":2.13,"committee":-0.010101,"eps":-10.199959,"divideRate":0,"volume":39530,"delay":0,"ttmEps":-10.199959,"open":2.2,"prevYearClose":80,"prevWeekClose":2.24,"prevMonthClose":2.02,"prevQuarterClose":3.14,"fiveDayClose":2.16,"twentyDayClose":2.5,"sixtyDayClose":7.299},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-06-22","symbol":"LABT","defaultRemindTime":1782135000000,"type":"split","dateTimestamp":1782100800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LABT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LABT","date":"2026-08-21","current":-0.219609,"percent":0.905405,"low":-12.282138,"twenty":-2.806803,"median":-1.276597,"eighty":-0.779084,"high":-0.62611,"avg":-2.731171,"sd":3.316371,"marketCap":5189616},"quantilePoints":[{"date":"2026-05-08","current":-12.282138,"twenty":-12.192813,"median":-11.891342,"eighty":-11.604759,"marketCap":47257207},{"date":"2026-05-15","current":-7.294845,"twenty":-12.043939,"median":-11.649421,"eighty":-11.314454,"marketCap":28067917},{"date":"2026-05-22","current":-2.865088,"twenty":-11.850402,"median":-11.258627,"eighty":-3.412052,"marketCap":11023817},{"date":"2026-05-29","current":-2.716586,"twenty":-11.716415,"median":-6.438817,"eighty":-2.758568,"marketCap":10452435},{"date":"2026-06-05","current":-2.512255,"twenty":-11.604759,"median":-3.225364,"eighty":-2.559299,"marketCap":9666247},{"date":"2026-06-12","current":-2.69016,"twenty":-11.537766,"median":-2.813168,"eighty":-2.512255,"marketCap":10350760},{"date":"2026-06-18","current":-2.241304,"twenty":-11.42611,"median":-2.776507,"eighty":-2.512255,"marketCap":8623724},{"date":"2026-06-26","current":-1.276597,"twenty":-10.242559,"median":-2.72924,"eighty":-2.388094,"marketCap":4911883},{"date":"2026-07-02","current":-1.116845,"twenty":-7.294845,"median":-2.69016,"eighty":-1.477578,"marketCap":4725718},{"date":"2026-07-10","current":-0.893476,"twenty":-5.58279,"median":-2.580737,"eighty":-1.276597,"marketCap":3780575},{"date":"2026-07-17","current":-0.62611,"twenty":-3.536511,"median":-2.512255,"eighty":-1.062695,"marketCap":2649266},{"date":"2026-07-24","current":-1.03562,"twenty":-3.225364,"median":-2.41344,"eighty":-0.92732,"marketCap":4382030},{"date":"2026-07-31","current":-0.653185,"twenty":-2.937143,"median":-2.34533,"eighty":-0.879262,"marketCap":2763829},{"date":"2026-08-07","current":-0.754716,"twenty":-2.857942,"median":-1.477578,"eighty":-0.80819,"marketCap":3193440},{"date":"2026-08-14","current":-0.78856,"twenty":-2.830251,"median":-1.371504,"eighty":-0.793975,"marketCap":3336643},{"date":"2026-08-21","current":-0.706322,"twenty":-2.806803,"median":-1.276597,"eighty":-0.779084,"marketCap":5189616}],"updateTime":1787565013359},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1977810588,"yearFounded":2006,"address":"8031 Cooper Creek Blvd.,Suite 103,University Park,Florida,United States","zipCode":"34201","officePhone":"941 225 2515","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://lakewoodamedex.com","stockEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":-0.3431},{"period":"3month","weight":-0.683},{"period":"6month","weight":-0.972},{"period":"ytd","weight":-0.972}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Lakewood-Amedex Biotherapeutics Inc.最初于2006年7月11日在特拉华州注册成立。该公司是一家私营制药公司，专注于通过开发其双磷酸霉素来应对抗菌素耐药性（AMR）的全球健康危机类抗菌剂。该公司的方法涉及一种新机制，旨在迅速破坏细菌膜的稳定性，这可能会降低耐药性发展的可能性。他们的先导化合物Nu-3目前正处于治疗感染的糖尿病足溃疡的临床试验中，被配制为外用凝胶，可提供快速的抗菌作用和靶向递送。除了糖尿病足溃疡，该公司正在探索在治疗复杂的尿路感染和肺部感染方面的应用。","exchange":"NASDAQ","name":"Lakewood-Amedex Biotherapeutics (Direct Listing)","nameEN":"Lakewood-Amedex Biotherapeutics (Direct Listing)"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LABT\",market:\"US\",,,undefined,":{"directors":[{"name":"Doug Manion","position":"Chairman of the Board and Independent Director"},{"name":"Kelvin Cooper","position":"Chief Executive Officer,Director and SVP Research & Development"},{"name":"Joseph Tucker","position":"Independent Director"},{"name":"Leonard J. DeRoma","position":"Independent Director"}],"executives":[{"name":"Kelvin Cooper","position":"Chief Executive Officer,Director and SVP Research & Development"},{"name":"Peter Ceccacci","position":"Chief Financial Officer and VP Administration"},{"name":"Thomas Balzer","position":"Chief Medical Officer and SVP Clinical Development"}]}}}